logo
Woman, 66 years old, gives birth to her 10th child: People 'should have more children'

Woman, 66 years old, gives birth to her 10th child: People 'should have more children'

Fox News27-03-2025

A 66-year-old woman in Germany has given birth to her 10th child.
Alexandra Hildebrandt, owner of the Wall Museum at Checkpoint Charlie in Berlin, welcomed her new son, Philipp, on March 19, according to today.com and other outlets.
The mom had her first child back in 1977, followed by eight children after she turned 50 — who were all born via C-section.
Her children include Svetlana, 45; Artiom, 36; twins Elisabeth and Maximilian, 12; Alexandra, 10; Leopold, 8; Anna, 7; Maria, 4 and Katharina, 2.
Hildebrandt told TODAY that she did not use any fertility drugs and did not have difficulty conceiving.
Her new baby Philipp was born via C-section at Charite Hospital in Berlin.
He weighed in at a "healthy" seven pounds, 13 ounces, although he was kept in an incubator.
For more Health articles, visit www.foxnews.com/health
In an interview with the German newspaper Bild, Hildebrandt shared her happiness in welcoming another child, noting that she feels "like I'm 35."
"We should encourage people to have more children!"
Professor Wolfgang Henrich, director of the Clinic for Obstetric Medicine at the Berlin Charite where Hildebrandt was treated, told Bild that her age and number of C-sections is an "absolute rarity in obstetric medicine and represented a challenge."
"Because of her particularly good physical constitution and mental strength, Ms. Hildebrandt managed the pregnancy well," he said.
"The operation was completely uncomplicated."
Hildebrandt confirmed with the publication, "I eat very healthily, swim regularly for an hour, run for two hours, don't smoke or drink, and have never used contraception."
"There is such a tendency to be unfriendly to children," Hildebrandt also told Bild.
"Many people would revise their judgment once they had contact with children. We should encourage people to have more children!"
Fox News Digital reached out to Hildebrandt for further comment.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments
COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments

Yahoo

timean hour ago

  • Yahoo

COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments

BioNTech is buying fellow German firm CureVac for approximately $1.25 billion as the COVID-19 vaccine maker moves to expand into cancer treatments. For each CureVac share they own, investors will get about $5.46 worth of BioNTech American Depositary Shares. CureVac is developing cancer medicines using the same mRNA technology that BioNTech uses for its COVID-19 (CVAC) shares skyrocketed 37% Thursday when the biotech company agreed to be bought by COVID-19 vaccine maker and fellow German firm BioNTech (BNTX) in an all-stock deal valued at about $1.25 billion. The purchase boosts BioNTech's move into producing new cancer treatments. CureVac said its investors will receive approximately $5.46 worth of BioNTech American Depositary Shares for each CureVac share they own. That a 34% premium to yesterday's closing price. The company noted it is "developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid ("mRNA")." BioNTech's COVID-19 shot is also mRNA-based. BioNTech co-founder and CEO Dr. Ugur Sahin said the deal is aimed at "advancing the development of innovative and transformative cancer treatments and establishing new standards of care for various types of cancer in the coming years." The transaction is expected to close this year and would see CureVac's operating subsidiary become a wholly owned subsidiary of BioNTech. Shares of CureVac soared to their highest level since December 2023. U.S.-listed shares of BioNTech were little changed and remain down nearly 8% year-to-date. Read the original article on Investopedia 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion

Yahoo

time2 hours ago

  • Yahoo

BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion

BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 billion. Each share of CureVac, a clinical-stage biotech company, will be exchanged for about $5.46 in BioNTech American depositary shares. Upon the deal's closing, CureVac shareholders are expected to own between 4% and 6% of the German developer of RNA vaccines and immunotherapies. ICE Raids Have Sent Latino Shoppers Into Hiding and Big Brands Are Hurting The Secret to Retaining the Best Employees: Ask Them These Four Questions Here's How Much Money the U.S. Is Earning From Tariffs, in Charts How Home Depot Became Ground Zero in Trump's Deportation Push Supply Chains Become New Battleground in the Global Trade War BioNTech Chief Executive Ugur Sahin said the plan is to bring complementary capabilities between the two companies together to develop transformative cancer treatments. CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech following the close of the transaction. As part of this plan, BioNTech will integrate CureVac's research and manufacturing site in Tübingen, Germany. The deal was unanimously approved by both companies' management and supervisory boards. It is expected to close in 2025. Shares of CureVac surged 29% to $5.25 in premarket trading. Write to Denny Jacob at Pulls Outlook as Sales Fall Bojangles Is Exploring a Sale While the Fried-Chicken Market Is Hot Why Bosses Should Give Feedback in the Morning The Audacious Reboot of America's Nuclear Energy Program Muted May Inflation Defies Tariff Fears Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Vaccine maker BioNTech to acquire fellow German pharma firm CureVac
Vaccine maker BioNTech to acquire fellow German pharma firm CureVac

Yahoo

time3 hours ago

  • Yahoo

Vaccine maker BioNTech to acquire fellow German pharma firm CureVac

BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its German pharmaceutical rival CureVac, the firm said on Thursday. BioNTech, which is based in the south-western city of Mainz, is planning to purchase all CureVac shares in a billion-dollar transaction to expand its expertise in the field of mRNA-based cancer therapies, it said. As per the agreement, each CureVac share is to be sold for around $5.46, which would correspond to a valuation of the Tübingen-based company of approximately $1.25 billion. The completion of the acquisition is subject to regulatory approvals and is expected to close by the end of 2025, BioNTech said, with CureVac shareholders to hold between 4% and 6% of BioNTech as a result. Both firms, which are listed on New York's Nasdaq exchange, made headlines during the coronavirus pandemic when they joined the race to develop an effective vaccine against the virus. While CureVac failed to achieve a breakthrough, the mRNA-based vaccination developed by BioNTech in less than a year was widely used to curb the spread of the virus and brought massive profits for the firm. BioNTech now focuses on cancer immunotherapies and aims to submit its first application for approval in the United States by the end of this year for a type of next-generation chemotherapy for uterine cancer. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store